News
-
-
-
-
PRESS RELEASE
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Kuros Biosciences AG reports significant growth in direct MagnetOs sales (163%) and total medical device sales (153%) in 2023. Positive EBITDA achieved. Plans for continued sales growth and profitability in 2024 -
-
PRESS RELEASE
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
Kuros Biosciences to report full-year financial results for 2023 and provide corporate update on March 13, 2024, with a conference call and webcast scheduled. Company overview and contact information included -
PRESS RELEASE
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
Kuros Biosciences to present at the CG 2024 Musculoskeletal Conference in San Francisco, discussing its MagnetOs portfolio of products for spinal fusion. CEO Chris Fair and other executives will attend, with a replay available for 90 days. Kuros Biosciences is a leader in next generation bone graft technologies -
PRESS RELEASE
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
Kuros Biosciences receives US FDA 510K clearance for MagnetOs Granules for interbody use and regulatory clearance in New Zealand. The company expands its international presence with an exclusive distribution agreement, extending the MagnetOs portfolio and bringing an advanced bone graft technology to the local medical community -
-
PRESS RELEASE
Kuros Biosciences Reports Results for First Half 2023
